3). Such patients are unable to absorb the macronutrients and/or water and electrolytes that 69 they need and require intravenous supplementation (1) . Although a potentially life-saving 70 treatment for people with IF, HPN imposes restrictions on an individual's life (2) . 71 Administering HPN is an invasive and time-consuming procedure requiring in-depth training 72 on the aseptic technique for patient and / or caregiver. Due to the nature of the treatment and 73 its associated complications (3, 4) HPN affects the quality of life (QoL) of patients (5) . 74 Previous research in this field has focused on the measurement of health-related quality of 75 life (HRQL) (6, 7) . HRQL differs from QoL as it is concerned with the impairments and 76 functional limitations that are of interest to health professionals, yet may not be of specific 77 concern to the patients themselves (8) . Furthermore, HRQL is only designed to assess clinical Health services are moving away from a fee for service model to outcomes based 82 commissioning (OBC) and reimbursement (OBR). Consequently, payers are becoming more 83 interested in the concept of patient value (9) . Such an approach requires the availability of a 84 patient-centric measure of value. Changes in patient value can then be related to the cost of 85 the intervention. While QoL clearly provides an estimation of patient value, HRQL does not.
86
To obtain a holistic picture of the impact of a condition and prescribed interventions on a 87 patient (patient value), it is essential to determine QoL (8) .
88
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Life questionnaire (HPN-QoL) (11) . More recently, the SBS-QoL has been developed, 92 specific for people with short bowel syndrome (12) . The SF-36, HPN-QoL and SBS-QoL all 93 assess HRQL. Furthermore, all three measures applied Classical Test Theory in their 94 development which has been largely replaced by Item Response Theory (IRT) in instrument 95 development. The application of IRT, and particularly Rasch analysis, greatly improves the 96 precision of measurement [13] .
97
To date, no measure has been developed that assesses the patient value of HPN. The most 98 widely implemented method of evaluating patient value is the needs-based model (14) . This 99 argues that disease and its treatment influence an individual's ability to fulfil his or her 
146
The same survey pack (excluding the NHP) was sent to a subset of respondents two weeks 147 after they had returned the first completed package, to assess reproducibility. the items do not work together to form a scale (21) . 168 Reproducibility of the PNIQ was assessed using Spearman's rank correlations of the scores at 169 each administration. A correlation of 0.85 or above is required to indicate that the scales are 170 adequately reproducible and that they produce low levels of random measurement error (22) .
171
To assess convergent validity, PNIQ scores were correlated with the NHP section scores Other 0 (0) 1 (6.7) 27 (11.5)
Duration of being on HPN (years)
Mean (SD) 7.2 (8.4) 7.2 (7.1) 6.9 (7.4)
Frequency of HPN (nights per week)
Mean (SD Table 3 The mildest and severest items for the PNIQ Scores on the PNIQ did not differ by gender, age, underlying disease (Crohn's versus other), 267 primary mechanism of IF (short-bowel versus other). The results of these analyses are shown 268 in Table 6 . Table 6 Associations between PNIQ and demographic factors. 
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